Fei Zhan

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Platinum-based chemotherapy is emerging as the first line of treatment for castration resistant prostate cancer. Among the family of platinum (IV)-based compounds, a member known as CPA-7 inhibits the growth of multiple cancer cell lines. However, how and to what extent CPA-7 elicits its anti-prostate cancer effects in vivo is largely unknown. In this(More)
  • 1